MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
Status:
Completed
Trial end date:
1996-07-01
Target enrollment:
Participant gender:
Summary
224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78)
or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone
antibiotic.